The insider sales are de minimis relative to market cap and are clearly tied to option exercise programs. No bearish signal. Monitor the next 10-Q for any change in Tyvaso DPI growth trajectory or competitive dynamics in inhaled prostacyclins.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 8 $564.94entry
- T+1 · 6mo ago +0.87%α +0.65% · $569.88
- T+5 · 6mo ago +0.64%α +0.43% · $568.58
- T+20 · 5mo ago −3.58%α −3.80% · $544.69
- T+60 · 3mo ago −8.13%α −12.49% · $519.01
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Three top executives at United Therapeutics (CEO, CFO, General Counsel) executed option exercises and sold a portion of the resulting shares in the week following the company's Q1 2026 earnings release. Total open-market sales were $1.44M, or ~0.006% of the $24.2B market cap, a trivial amount relative to company size. The sales appear to be routine tax- and cash-management transactions tied to option exercises, not a signal of deteriorating fundamentals.
Key Financial Metrics
Key Facts
- Total open-market sales by 3 insiders: $1.44M (0.006% of market cap)
- CEO Martine Rothblatt sold 2,871 shares for $1.63M across 4 trades, but also exercised options on 38,000 shares (mostly non-cash)
- CFO James Edgemond sold 1,849 shares for $1.05M, while exercising options on 20,000 shares
- EVP Paul Mahon sold 80 shares for $46.6K, exercising options on 8,300 shares
- All sales occurred after the May 6 earnings release, which showed a 2% revenue decline and 15% net income decline YoY
- The cluster is 6 days post-earnings, insiders were cleared to trade after the public release of results
Financial Impact
Open-market sales of $1.44M represent 0.006% of $24.2B market cap, immaterial
Risk Factors
- Q1 revenue declined 2% YoY and net income fell 15%, continued erosion in Nebulized Tyvaso and Remodulin could pressure future results
- Cost of sales surged 44% YoY, partly due to a $26.8M inventory reserve from a commercial supply agreement
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-UTHR-1778621182895 |
Track record
123 reports on UTHR
4 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +10.30% at T+20 after the Oct 14, 2026 report. 5 of 9 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 3/10 Entry price pending
- Nov 13, 20263d ago Insider Cluster Bearish 4/10 Entry $597.50 Now $587.88 +1.61% settles Nov 23
- Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $591.17 Now $587.88 −0.56% settles Nov 20
- Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $595.66 Now $587.88 −1.31% settles Nov 18
- Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $582.46 to $587.88 Now $587.88 +0.93% ▲ +0.93% +2.62% vs SPY
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 4, 202612d ago SC 13G/A Neutral 2/10 Entry $565.72 to $593.31 Now $587.88 +3.92% ▲ +4.88% +1.59% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers